Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott Schoninger, Stacy W. Blain
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 1, pp. 3-12
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Massimo Cristofanilli, Hope S. Rugo, Seock‐Ah Im, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 16, pp. 3433-3442
Open Access | Times Cited: 127
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
Andrea C. Chaikovsky, Chuan Li, Edwin E. Jeng, et al.
Nature (2021) Vol. 592, Iss. 7856, pp. 794-798
Open Access | Times Cited: 115
Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 98
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy
Yaniv Kazansky, Daniel Cameron, Helen S. Mueller, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 965-981
Open Access | Times Cited: 18
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan M. Goldberg, Ricardo Pastorello, Tuulia Vallius, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 99
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Qing-Yun Chong, Ze-Hui Kok, Ngoc-Linh-Chi Bui, et al.
Pharmacological Research (2020) Vol. 156, pp. 104686-104686
Closed Access | Times Cited: 86
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma Asghar, Ruhi Kanani, Rebecca Roylance, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 66
CDK inhibitors from past to present: A new wave of cancer therapy
Muhammad Jameel, Kinjal Bhadresha, Hang Fai Kwok
Seminars in Cancer Biology (2022) Vol. 88, pp. 106-122
Open Access | Times Cited: 57
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer
Pierre-Étienne Heudel, Jean‐Sébastien Frenel, Cécile Dalban, et al.
JAMA Oncology (2022) Vol. 8, Iss. 7, pp. 1001-1001
Open Access | Times Cited: 48
CDK4: a master regulator of the cell cycle and its role in cancer
Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, et al.
Genes & Cancer (2022) Vol. 13, pp. 21-45
Open Access | Times Cited: 48
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
Ciara C. O’Sullivan, Robert Clarke, Matthew P. Goetz, et al.
JAMA Oncology (2023) Vol. 9, Iss. 9, pp. 1273-1273
Open Access | Times Cited: 26
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 23
Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2− breast tumor cells
Tarek M. Zikry, Samuel C. Wolff, Jolene S. Ranek, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 7
Open Access | Times Cited: 9
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays
Reece Foy, Kah Xin Lew, Adrian T. Saurin
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Predictive biomarkers for personalized medicine in breast cancer
Sylvie Rodrigues-Ferreira, Clara Nahmias
Cancer Letters (2022) Vol. 545, pp. 215828-215828
Open Access | Times Cited: 34
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana-Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 21
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
Sung Soo Kim, Jessica Armand, Anton Safonov, et al.
Cell Reports (2023) Vol. 42, Iss. 11, pp. 113198-113198
Open Access | Times Cited: 19
CIP/KIP and INK4 families as hostages of oncogenic signaling
Lucia Csergeová, David Krbušek, Radoslav Janoštiak
Cell Division (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 6
<p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p>
Yanmei Wu, Yu Zhang, Hao Pi, et al.
Cancer Management and Research (2020) Vol. Volume 12, pp. 3477-3487
Open Access | Times Cited: 45
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Lisa Scheiblecker, Karoline Kollmann, Veronika Sexl
Pharmaceuticals (2020) Vol. 13, Iss. 12, pp. 418-418
Open Access | Times Cited: 41
The structure of the human cell cycle
Wayne Stallaert, Katarzyna M. Kedziora, Colin D. Taylor, et al.
Cell Systems (2021) Vol. 13, Iss. 3, pp. 230-240.e3
Open Access | Times Cited: 37
The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance
Mary Abdelmalak, Rajanbir Singh, Mohammed Anwer, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5388-5388
Open Access | Times Cited: 24
CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity – a narrative review
D. Pavlović, Danijela Niciforovic, Dragana Papic, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 15
Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models
Christin Riess, Dirk Koczan, Björn Schneider, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 29
Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 1408-1420
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top